The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks specific targets such as estrogen, progesterone, and HER2 receptors. TNBC affects one in eight women in the United States, making up 15–20% of breast cancer cases. Patients with TNBC can develop resistance to chemotherapy over time, leading to treatment failure. Therefore, finding other options like natural products is necessary for treatment. The advantages of using natural products sourced from plants as anticancer agents are that they are less toxic, more affordable, and have fewer side effects. These products can modulate several cellular processes of the tumor microenvironment, such as proliferation, migration, angiogenesis, cell cycle arrest, and apoptosis. The phosphatidyl inositol 3-kinase (PI3K)-AKT signaling pathway is an important pathway that contributes to the survival and growth of the tumor microenvironment and is associated with these cellular processes. This current study examined the anticancer effects of fucoxanthin, a marine carotenoid isolated from brown seaweed, in the MDA-MB-231 and MDA-MB-468 TNBC cell lines. The methods used in this study include a cytotoxic assay, PI3K-AKT signaling pathway PCR arrays, and Wes analysis. Fucoxanthin (6.25 µM) + TNF-α (50 ng/mL) and TNF-α (50 ng/mL) showed no significant effect on cell viability compared to the control in both MDA-MB-231 and MDA-MB-468 cells after a 24 h treatment period. PI3K-AKT signaling pathway PCR array studies showed that in TNF-α-stimulated (50 ng/mL) MDA-MB-231 and MDA-MB-468 cells, fucoxanthin (6.25 µM) modulated the mRNA expression of 12 genes, including FOXO1, RASA1, HRAS, MAPK3, PDK2, IRS1, EIF4EBP1, EIF4B, PTK2, TIRAP, RHOA, and ELK1. Additionally, fucoxanthin significantly downregulated the protein expression of IRS1, EIF4B, and ELK1 in MDA-MB-231 cells, and no change in the protein expression of EIF4B and ELK1 was shown in MDA-MB-468 cells. Fucoxanthin upregulated the protein expression of RHOA in both cell lines. The modulation of the expression of genes and proteins of the PI3K-AKT signaling pathway may elucidate fucoxanthin’s effects in cell cycle progression, apoptotic processes, migration, and proliferation, which shows that PI3K-AKT may be the possible molecular mechanism for fucoxanthin’s effects. In conclusion, the results obtained in this study elucidate fucoxanthin’s molecular mechanisms and indicate that fucoxanthin may be considered a promising candidate for breast cancer-targeted therapy.

[1]  K. Soliman,et al.  Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells , 2023, Molecules.

[2]  M. Pan,et al.  Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  K. Soliman,et al.  Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation , 2022, International journal of molecular sciences.

[4]  Claire E. Tocheny,et al.  The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target , 2022, Life.

[5]  Long Chen,et al.  Advances in Fucoxanthin Research for the Prevention and Treatment of Inflammation-Related Diseases , 2022, Nutrients.

[6]  C. Shao,et al.  TNFα and IFNγ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property , 2022, Stem Cell Research & Therapy.

[7]  L. Jia,et al.  Fucoxanthin prevents breast cancer metastasis by interrupting circulating tumor cells adhesion and transendothelial migration , 2022, Frontiers in Pharmacology.

[8]  I. V. Ogungbe,et al.  Carotenoids in Drug Discovery and Medicine: Pathways and Molecular Targets Implicated in Human Diseases , 2022, Molecules.

[9]  T. Boggon,et al.  SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP , 2022, Nature Communications.

[10]  Zunnan Huang,et al.  Fucoxanthin Inactivates the PI3K/Akt Signaling Pathway to Mediate Malignant Biological Behaviors of Non-Small Cell Lung Cancer , 2022, Nutrition and cancer.

[11]  Tariq Ahmad Masoodi,et al.  Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  M. Muchtaridi,et al.  Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line , 2022, Molecules.

[13]  H. Kwan,et al.  Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer , 2022, Marine drugs.

[14]  Md. Abdul Hannan,et al.  A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights , 2022, Marine drugs.

[15]  Liangke Zhang,et al.  Promoting Apoptosis, a Promising Way to Treat Breast Cancer With Natural Products: A Comprehensive Review , 2022, Frontiers in Pharmacology.

[16]  Weilin Wang,et al.  ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis , 2021, Frontiers in Molecular Biosciences.

[17]  Kui-Sheng Chen,et al.  Targeting PI3K/Akt signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[18]  S. Volinia,et al.  The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2 , 2021, Cells.

[19]  Shile Huang,et al.  Deficiency of eIF4B Increases Mouse Mortality and Impairs Antiviral Immunity , 2021, Frontiers in Immunology.

[20]  E. Castellano,et al.  The Importance of Being PI3K in the RAS Signaling Network , 2021, Genes.

[21]  Xiang Xu,et al.  TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell , 2021, International journal of biological sciences.

[22]  P. Foden,et al.  FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity , 2021, NPJ breast cancer.

[23]  D. Purwaningsari,et al.  The Effect of Brown Seaweed (Sargassum sp.) Extract on Apoptosis Process in Breast Cancer – A Literature Review , 2021, Indian Journal of Forensic Medicine & Toxicology.

[24]  Prachi Mishra,et al.  The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment , 2021, Frontiers in Immunology.

[25]  S. Varambally,et al.  Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women , 2021, Translational oncology.

[26]  Hongmin Li,et al.  Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications , 2021, Bioscience reports.

[27]  K. Michalska,et al.  Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings , 2021, BMC cancer.

[28]  M. Greabu,et al.  PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects , 2020, International journal of molecular sciences.

[29]  L. Kenner,et al.  The Implications of PDK1–4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance , 2020, Frontiers in Oncology.

[30]  B. Chénais,et al.  Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy , 2020, International journal of molecular sciences.

[31]  Ana-Teresa Maia,et al.  Differential expression between African-ancestry and White patients diagnosed with Triple-Negative Breast Cancer: EGFR, Myc, Bcl2 and β-Catenin as ancestry-associated markers , 2020, bioRxiv.

[32]  P. Sun,et al.  Role of RASA1 in cancer: A review and update , 2020, Oncology reports.

[33]  Kang Yang,et al.  Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D , 2020, The Journal of international medical research.

[34]  Hui Chen,et al.  Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. , 2020, Journal of ethnopharmacology.

[35]  J. Haybaeck,et al.  Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate , 2020, Cancers.

[36]  X. Bian,et al.  Triple-negative breast cancer molecular subtyping and treatment progress , 2020, Breast Cancer Research.

[37]  M. Mercogliano,et al.  Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer , 2020, Frontiers in Oncology.

[38]  Jason B. White,et al.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations , 2020, Cancers.

[39]  A. Chinnathambi,et al.  Fucoxanthin inhibits cell proliferation and stimulates apoptosis through downregulation of PI3K/AKT/mTOR signaling pathway in human ovarian cancer cells , 2020 .

[40]  J. Buján,et al.  Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR , 2020, Journal of oncology.

[41]  Hailin Tang,et al.  CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1 , 2019, Aging.

[42]  M. Galiè RAS as Supporting Actor in Breast Cancer , 2019, Front. Oncol..

[43]  G. Hoxhaj,et al.  The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism , 2019, Nature Reviews Cancer.

[44]  V. Jain,et al.  PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. , 2019, Drug discovery today.

[45]  T. Fehm,et al.  Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients , 2019, Breast Cancer Research and Treatment.

[46]  K. Arunkumar,et al.  Fucoxanthin , 2019, Biochemical and Environmental Bioprocessing.

[47]  H. Farhan,et al.  Multifaceted Rho GTPase Signaling at the Endomembranes , 2019, Front. Cell Dev. Biol..

[48]  N. Tsuchida,et al.  RAS Mutations in Human Cancers: Roles in Precision Medicine. , 2019, Seminars in cancer biology.

[49]  Stephen P. Ethier,et al.  Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer , 2019, BMC Cancer.

[50]  M. Pellegrino,et al.  Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells , 2019, Journal of Experimental & Clinical Cancer Research.

[51]  L. Pusztai,et al.  Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women , 2019, Breast Cancer Research and Treatment.

[52]  W. Xiang,et al.  Induction of Apoptosis in Human Glioma Cells by Fucoxanthin via Triggering of ROS-Mediated Oxidative Damage and Regulation of MAPKs and PI3K-AKT Pathways. , 2019, Journal of agricultural and food chemistry.

[53]  Linlin Sui,et al.  Fucoxanthin inhibits tumour‐related lymphangiogenesis and growth of breast cancer , 2019, Journal of cellular and molecular medicine.

[54]  Min Song,et al.  Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors , 2018, BMC Systems Biology.

[55]  Q. Peng,et al.  The Akt pathway in oncology therapy and beyond (Review) , 2018, International journal of oncology.

[56]  C. Zou,et al.  CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma , 2018, Journal of experimental & clinical cancer research : CR.

[57]  R. García-Becerra,et al.  Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer , 2017, Journal of Biomedical Science.

[58]  E. Lam,et al.  The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance , 2017, Seminars in cancer biology.

[59]  Xiao Meng,et al.  Dietary Natural Products for Prevention and Treatment of Breast Cancer , 2017, Nutrients.

[60]  Y. Satomi Antitumor and Cancer-preventative Function of Fucoxanthin: A Marine Carotenoid. , 2017, Anticancer research.

[61]  Debarshi Kar Mahapatra,et al.  Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies. , 2016, Current pharmaceutical design.

[62]  Yugang Liu,et al.  Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma Cells , 2016, Neurochemical Research.

[63]  Luc J. Martin Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment , 2015, Marine drugs.

[64]  H. El-Hadaad,et al.  Current approaches in treatment of triple-negative breast cancer , 2015, Cancer biology & medicine.

[65]  Yibo Tang,et al.  Fucoxanthin: A Promising Medicinal and Nutritional Ingredient , 2015, Evidence-based complementary and alternative medicine : eCAM.

[66]  K. Dahlman-Wright,et al.  AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer , 2015, Oncotarget.

[67]  Jin-hai Tang,et al.  Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines , 2014, Molecular medicine reports.

[68]  Julie M. Madden,et al.  Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer , 2014, Breast Cancer Research and Treatment.

[69]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[70]  K. Miyashita,et al.  Fucoxanthin: A Marine Carotenoid Exerting Anti-Cancer Effects by Affecting Multiple Mechanisms , 2013, Marine drugs.

[71]  Kaleigh Fernald,et al.  Evading apoptosis in cancer. , 2013, Trends in cell biology.

[72]  C. Kingsley,et al.  IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. , 2013, Cancer letters.

[73]  C. Piyathilake,et al.  Triple Negative Breast Cancer – An Overview , 2012, Hereditary genetics : current research.

[74]  B. Hemmings,et al.  PI3K-PKB/Akt pathway. , 2012, Cold Spring Harbor perspectives in biology.

[75]  Andrew D. Sharrocks,et al.  ELK1 Uses Different DNA Binding Modes to Regulate Functionally Distinct Classes of Target Genes , 2012, PLoS genetics.

[76]  Mingli Liu,et al.  The emerging role of CXCL10 in cancer (Review). , 2011, Oncology letters.

[77]  K. Miyashita,et al.  Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver. , 2011, Journal of agricultural and food chemistry.

[78]  N. Sonenberg,et al.  eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways , 2010, Cell cycle.

[79]  Patrick Mayeux,et al.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia , 2010, Haematologica.

[80]  W. Link,et al.  Understanding FOXO, new views on old transcription factors. , 2010, Current cancer drug targets.

[81]  J. Prat,et al.  Expression profiling of 22 genes involved in the PI3K–AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations , 2010, Modern Pathology.

[82]  C. Gardana,et al.  Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. , 2008, Journal of agricultural and food chemistry.

[83]  D. Tindall,et al.  FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.

[84]  I. Frahm,et al.  TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways , 2008 .

[85]  N. Ahmad,et al.  RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. , 2006, Cancer research.

[86]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[87]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[88]  F. Alenzi,et al.  Links between apoptosis, proliferation and the cell cycle , 2004, British journal of biomedical science.

[89]  Daniel R. Caffrey,et al.  LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF , 2003, The Journal of experimental medicine.

[90]  H. Shu,et al.  TIRP, a Novel Toll/Interleukin-1 receptor (TIR) Domain-containing Adapter Protein Involved in TIR Signaling* , 2003, Journal of Biological Chemistry.

[91]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[92]  A. Bresnick,et al.  Roles of Rho-associated Kinase and Myosin Light Chain Kinase in Morphological and Migratory Defects of Focal Adhesion Kinase-null Cells* , 2002, The Journal of Biological Chemistry.

[93]  A. Sharrocks,et al.  The ETS Domain Transcription Factor Elk-1 Contains a Novel Class of Repression Domain , 2002, Molecular and Cellular Biology.

[94]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[95]  Y. Sugiyama,et al.  Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases. , 2002, Biochimica et biophysica acta.

[96]  K. Miyashita,et al.  Carotenoids affect proliferation of human prostate cancer cells. , 2001, The Journal of nutrition.

[97]  P. Tsichlis,et al.  PDK2: A Complex Tail in One Akt , 2001, Science's STKE.

[98]  M. Kasten,et al.  Cell cycle and apoptosis. , 2000, Neoplasia.

[99]  H. Nishino,et al.  Cancer prevention by carotenoids. , 1998, Mutation research.

[100]  E. G. Nabel,et al.  NATIONAL CANCER INSTITUTE , 1993, Definitions.

[101]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[102]  I. Frahm,et al.  TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. , 2008, Experimental cell research.

[103]  R. Assoian,et al.  Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. , 1997, Current opinion in cell biology.